Oncology
出版商：S. Karger AG · ISSN：0030-2414, 1423-0232 · 国家/地区：CH · 类型：journal
研究主题：Cancer Treatment and Pharmacology · Hepatocellular Carcinoma Treatment and Prognosis · Colorectal Cancer Treatments and Studies · Diverse Scientific and Economic Studies · Human auditory perception and evaluation
核心指标
- 影响因子(JCR 2025):1.900
- JCR 分区:Q4(ONCOLOGY)
- 中科院分区(2025):医学 4区;小类:ONCOLOGY 肿瘤学 4区
- 新锐分区(2026):医学 4区
- SJR:0.596(Q2)
- h-index:125
- i10 指数:3390
- 近两年篇均被引:1.66
- 载文量 6617 · 总被引 157825
逐年趋势
- 近年影响因子:2021 3.73 → 2022 3.5 → 2023 2.5 → 2024 1.8 → 2025 1.9
- 近年 SJR:2021 0.785(Q2) → 2022 0.856(Q2) → 2023 0.832(Q2) → 2024 0.747(Q2) → 2025 0.596(Q2)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- Kidney International Supplements — IF 89.6 · JCR Q1 · 中科院2区
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
- World Psychiatry — IF 65.8 · JCR Q1 · 中科院1区(Top)
常见问题
《Oncology》的影响因子是多少?
根据 JCR 2025 年数据,《Oncology》的最新影响因子(IF)为 1.900。
《Oncology》是几区期刊?
《Oncology》中科院分区(2025年版)为医学4区,JCR 分区为 Q4。
本刊近期代表论文
- A Real-World Pharmacovigilance Analysis for Demethylation Drug: Findings from the FDA Adverse Event Reporting Database (2025 · 被引 4)
- Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study (2025 · 被引 1)
- Comprehensive Analysis of the Relationship between Cuproptosis-Related Gene GCSH and Prognosis, Tumor Microenvironment Infiltration, and Therapy Response in Endometrial Cancer (2023 · 被引 6)